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Norovirus (NoV) is one of the most ubiquitous factors contributing to acute gas-
troenteritis that causes widespread outbreaks in travel industry, military, or health-
care facilities. NoV could lead to serious symptoms and result in severe societal costs 
worldwide. Surprisingly, there has been no available licensed vaccines, albeit there 
are ongoing pre-clinical or clinical trials of several candidate vaccines. Development 
of effective universal vaccines has been found difficult clinically due to the fre-
quent point mutations and a lack of robust animal model and cell culture system. 
Preclinical studies showed that vaccines with virus-like particles (VLPs) have high 
immunogenicity and efficacies and were demonstrated to be protective and safe. 
Recent in vitro research also suggests that human intestinal enteroids can enhance 
our understanding of protection mechanism and give guidance for vaccine develop-
ment. Overall, this chapter will give a comprehensive review of the current challenge 
and progress of clinical findings, efficacy/safety of the developing vaccines, and 
antiviral drug developments for NoV in clinical trials or preclinical investigations.
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1. Introduction
Norovirus (NoV) has been the leading cause contributing to acute gastroenteritis 
worldwide [1]. The Product Development for Vaccines Advisory Committee of the 
World Health Organization (WHO) also recognized NoV as a priority disease for 
vaccine development [1]. It was estimated that the global burden of NoV disease 
was more than 677 million cases and 213515 deaths annually [1]. Surveillance stud-
ies in the United States suggested that NoV leads to ~20% of acute gastroenteritis in 
children under 5 years old [2–4]. It was also demonstrated that rate of NoV gastroen-
teritis in this group of age exceeds that of rotavirus gastroenteritis [2–4]. Particularly 
high rates of mortality and illness requiring medical care present at age > 65 years 
and under 5 year olds, respectively [4, 5]. Sudden onset of symptoms including 
watery diarrhea, vomiting, abdominal cramps, malaise, and fever are commonly seen 
and usually more serious occur in immunocompromised or elderly individuals [1].
NoVs are small (diameter, 35–40 mm), non-enveloped, positive, and single-
stranded RNA viruses belonging to the Caliciviridae family [1, 6]. With Norovirus 
being one of the genera of the family, it could be classified into seven genogroups 
based on the phylogenetic analysis of the virus genome and capsid sequence, where 
GI, GII, and GIV infect humans and GI and GII are major groups causing human 
infections (Table 1) [1]. GI and GII genogroups could be respectively subdivided 
into 9 and 25 genotypes based on the viral capsid protein (VP1) sequence.
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Development of NoV vaccines has been in progress for more than a decade. 
There has been no licensed vaccines for prevention of NoV infections [1]. Although 
there are several candidates that have gone through clinical trials such as the 
Adenovirus type 5 vaccine expressing the GI.1 capsid protein (Vaxart) and the 
bivalent GI and GII.4 VLP vaccine (Takeda), development of a vaccine with broad-
spectrum antiviral effects against various or newly emerging viral strains are of 
increasingly needed [1].
2. Clinical observations
It was estimated that one in six patients with acute diarrhea has NoV as the caus-
ative pathogen [7, 8]. Nov is highly contagious and was estimated to release more 
than 30 million virus particles from vomiting [8–10]. The infecting dose are only 
10–100 virus particles to induce related symptoms, and the attack rate is more than 
50% [8–12]. Generally, the incubation period of NoV is from 24 to 48 hours. There’s 
no prodromal illness before the onset of the NoV, and the symptoms are usually 
explosive [8, 12, 13]. Predominant symptoms include fever, vomiting, diarrhea and 
clinically lasts for 2 to 3 days [8, 14]. Vomiting and diarrhea are the most common 
symptoms that occurs in 70% and 90% infected patients, respectively.
In a 3-year multicentered study presenting clinical features of Norovirus in 
Taiwan children, fever and vomiting are found to stop in approximately 3 and 
2 days, respectively [8, 14]. However, diarrhea lasts as long as around 6 days [8, 14]. 
Malnutrition, dehydration, and dysfunctional intestinal barrier will also worsen the 
illness [7, 8].
Arias et al. [15] also performed a prospective study provided evidence that 
symptoms such as abdominal pain, vomiting, and myalgia are common in both chil-
dren and adults, while myalgia and diarrhea are more common seen in adults. There 
was no difference found between male and female subjects (Figure 1). However, 
fever and abdominal pain were observed to be more frequent in male than in female 
individuals (34.5% vs. 28.9%, p = 0.022; 70.8% vs. 64.4%, p = 0.013, respectively) 
(Figure 1) [15]. In another stratified factor, age may play as an influential role in 
symptoms of subjects. It was noticed that risk of diarrhea was higher in elderly 
(> 65 years) group (OR; 2.61; 95% CI: 1.93–3.55) (Figure 2) [15]. Vomiting and 
abdominal pain were found to be more frequent in children at age < 5 years old 
(Figure 2) [15].
It was reported that there are 3 to 10 episodes of diarrhea per day in patients with 
NoV gastroenteritis [16]. Moreover, NoV gastroenteritis could be a major threat to 
Genus Genogroup Genotypes Species infected
Lagovirus GI GI.1–9 Human
GII GII.1–23 Human and pig
Nebovirus GIII GIII.1–2 Cow and sheep
Norovirus GIV GIV.1–2 Human, cat, dog, and lion
Sapovirus GV Mouse and rat
Vesivirus GVI GVI.1–2 Dog
GVII Dog
Table 1. 
Classification of the Caliciviridae family, among which GI and GII are the most prevalent genogroups for NoV 
infections in human (adapted from Melhem [1] and Cortes-Penfield [33]).
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patients especially with hematopoietic stem cell transplant or chemotherapy [17]. It 
was also reported that NoV could infect individuals many times or with more than 
one NoV strain during the course of an outbreak [7, 8].
2.1 NoV vaccines in development
Candidate NoV vaccines in development are either in clinical trials or still in pre-
clinical stages (Table 2). There have been two groups of virus-like particles (VLP)-
based vaccines in development. One is a combination of GI.1 and GII.4 VLPs that 
is in human clinical trials, whereas the other is a mixture of GI.3 and GII.4 VLPs, 
which is in preclinical developments [4] (Table 2). In addition, there are two other 
groups of vaccines based on recombinant adenovirus serotype 5 vectors express-
ing NoV VP1. One is currently in Phase I and is based on GI.1 NoV sequence, and 
the other is based on GI.4 sequence and developed my Chinese Center for Disease 
Control and Prevention [4] (Table 2). Vaccines in development will be described in 
the following sections in this chapter.
Figure 1. 
Distribution of symptoms of NoV based on male and female among 1544 cases from 2004 to 2005 in Catalonia, 
Spain (adapted from arias et al. [15]).
Figure 2. 
NoV symptoms at two different age groups of children (< 5 years) and elderly (> 65 years) among 1544 cases 
from 2004 to 2005 in Catalonia, Spain (adapted from arias et al. [15]).
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2.1.1 GI.1/Gll.4 VLP vaccines
Initially, the VLP-type NoV vaccine in human had oral administration of 
unadjuvanted GI.1 NoV VLPs. Results showed that there were 4-fold increments 
of virus-specific serum IgG level and no adverse events in 83% of the recipients 
[18]. In light of this finding, there’s development of a VLP vaccine adjuvanted with 
mucoadhesin and monophosphoryl lipid A for intranasal delivery [19, 20]. The vac-
cine was a Phase I study with double-blind and placebo-controlled design. Results 
showed that it could induce NoV-specific IgG and IgA memory B cells, IgG, and 
IgA. No occurrence of serious adverse events [4, 19, 20].
Another randomized, double-blind, and placebo-controlled study that assessed 
efficacy of intranasally delivered vaccine gave subjects challenged with ~10 human-
infectious doses of Norwalk virus 2 doses of vaccine/placebo [4, 21]. Results showed 
that a 32% absolute reduction of the risk (37% vs. 69%; P = 0.06) for gastroenteritis 
in the vaccine recipients. The result was associated with the increase of NoV-
specific antibody levels including IgA and serum HBGA-blocking antibodies [4, 21]. 
However, there was no significant reduction of the duration of illness or symptoms. 
Moreover, local nasal symptoms including sneezing, itching, stuffiness, and nasal 
discharge were more common after second dose of vaccination in vaccine arm, 
regardless that there were no occurrence of serious adverse events [4, 21].
On the other hand, the prevalence of GII.4 NoV resulted in the addition of a GII.4 
VLP component to GI.1 VLPs to generate bivalent vaccines [4, 22]. Previous preclinical 
study showed that the addition of GII.4 VLP, based on 3 different sequences of GII.4 
NoV strain variants, led to induction of reactive antibodies to heterologous GI.3, GII.1, 
GII.3, and GIV.1 NoVs [4, 22]. Also, a randomized and placebo-controlled clinical trial 
of a bivalent GI.1 and consensus GII.4 VLP vaccine adjuvanted with aluminum hydrox-
ide and monophosphoryl lipid A was delivered to subjects with a series of 2 intramus-
cular injections [4, 22, 23]. Developments of GI.1- and GII.4-specific serum antibody 
peaked at day 7 were observed after vaccination. No adverse events were distinguished. 
NoV-specific antibody-secreting cells, plasmablasts, and memory B cells were also 
evidenced. However, it was found that dose escalation did not lead to higher levels of 
NoV-specific antibodies. After first vaccine dose, HBGA-blocking antibodies were 
developed at high levels in all age groups (18–49, 50–64, and 65–85 years), whereas 
there was little additional increments in levels after second vaccination [4, 22, 23].
A bivalent vaccine targeting GII.4 NoV was also assessed through a randomized, 
double-blind, and placebo-controlled trial with 63 and 64 subjects received NoV 
vaccine and placebo vaccine, respectively [4, 24]. Among the participants, 56 and 
53 individuals were challenged with 4400 reverse-transcription polymerase chain 
reaction units of a GII.4 NoV variant, which was not included in the consensus 
GII.4 sequence. Although there were no statistical significance in the decrease of 
prevalence in gastroenteritis, milder symptoms were observed after NoV challenge. 
No reported adverse events. No reductions of duration of NoV illness and time from 














Phase IIb Takeda NoV VLP GI.1, GII.4 Intramuscular [25, 26]
Table 2. 
NoV vaccines under clinical trials (adapted from Nicolas et al. [4]).
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Another study for investigation of a bivalent GI.1/GII.4 vaccine is in Phase II 
clinical trials that prevention of NoV-related illness and infection after intranasally or 
intramuscularly administration were also demonstrated. The Phase IIb, double-blind, 
randomized, placebo-controlled, efficacy trial with participants from the US Navy 
was just performed (NCT02669121) [4, 25]. Results showed that increases of GI.1 and 
GII.4 HBGA-blocking antibodies in vaccines and in some placebo cases infected with 
GII.2 revealed the cross-activity in the immune responses to different genotypes [26].
Due to the lack of in vitro culture systems for human NoV, there has been no 
inactivated or live attenuated NoV particle vaccines developed [4]. Although there 
are 2 NoV candidate vaccines in human trials, the immediate development of vac-
cines based on NoV particles seems difficult [4].
2.1.2 Adenovirus vector-based GI.1 VP1 vaccines
It was evidenced that a recombinant serotype 5 adenovirus vector with expres-
sion of a GII.4 NoV VP1 was immunogenic in mice intranasally vaccinated [4, 27]. 
NoV-specific IgG and IgA in feces, respiratory mucosa, and serum were observed 
[4, 27]. It was also found by the same group that combination of booster vaccination 
using NoV VKPs and adenovirus vector could enhance immune responses [4, 27].
Another adenovirus vector-based NoV vaccine (VXA-GI.1-NN) expressing NoV 
major capsid protein VP1 from the GI.1 Norwalk virus that is orally administered 
is also in development [4, 28]. The immunogenicity and tolerability of the vaccine 
against H1N1 influenza expressing the same adenovirus-vectored platforms were 
reported [4, 29]. The VXA-GI.1-NN was announced to go through the completion of 
a Phase I trial (NCT02868073). Recent results showed that the vaccine had no dose-
limiting toxicities and only mild/moderate adverse events presented. Immunogenicity 
and tolerability end points of the vaccine were also reached [30]. Serum NoV-blocking 
antibody levels significantly increased in recipients. No adverse events observed.
In addition, a newest phase I (NCT03721549) GI.1 study (Lot 001-09NV) spon-
sored by the WCCT Global was also conducted to explore its efficacy with a controlled 
human infection model (CHIM). Results indicated that Lot 001-09NV could be a use-
ful challenge strain for vaccine studies aiming at the establishment of immune corre-
lates [31]. However, development of a multivalent vaccine is in need since the vaccine 
did not show consistently robust immune responses to heterotypic NoV strains [4, 29].
3. Drugs in clinical development
Candidate drugs for NoV treatments are still in the process of developments 
although there has been intensive need for effective NoV antivirals. Most candidates 
are still in the early stages of preclinical trials. Human NoV culture in enteroid 
system are frequently applied in the preclinical research to assess safety or efficacy 
of candidate drugs. Although the landscape for antiviral developments is frequently 
changed, this chapter will give a comprehensive review of the drugs that have been 
approved by regulatory agencies, previously or in the process of clinical trials.
3.1 Polymerase inhibitors
3.1.1 Nucleoside analogs
Among all NoV antiviral targets, the RNA-dependent RNA polymerase (RdRp) is 
one of the candidates identified to be effective in inhibition of NoV activity in preclini-
cal stages. The RdRp acts as an attractive antiviral therapy since it has the advantage 
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of lacking host homologs to minimize the chance of off-target adverse effects [32, 33]. 
The RdRp-targeting antivirals could be divided into two major classes: the nucleoside 
analogs (NAs) and the non-nucleoside inhibitors (NNIs). Typically, NAs inhibit RNA 
syntheses through mimicry of the generation of nucleoside triphosphate (NTPs) that 
lead to chain termination after incorporation [33, 34]. On the contrary, NNIs exert 
lower antiviral activity and bind allosterically to block rearrangements of conformation 
of the viral polymerase to form active replication complex [33, 35].
3.1.1.1 2CMC
Some of the NA-drugs were repurposed to treat human NoV since they have 
the mechanism of RNA synthesis inhibition for various kinds of viruses. One of 
the drugs is called 2CMC (2’-C-methylcytidine), which was originally served as an 
antiviral therapy for HCV. It also exhibited inhibition activities against flaviviruses 
such as West Nile virus, DENV, yellow fever virus [33, 36]. Valopicitabine, one of 
the oral 2CMC prodrug used against for HCV, was halted for development due to 
undesirable gastrointestinal effects reported [33, 37]. However, although the 2CMC 
was discontinued for clinical treatment, it has been widely served as a potential 
NoV-treating drug. It was found RNA synthesis of Norwalk replicon was dose-
dependently reduced by the 2CMC [33, 38]. Murine NoV (MNV) plaque and RNA 
synthesis were also demonstrated to be inhibited [33, 39].
3.1.1.2 T705 (Flavipiravir)
T705 is a purine analog that showed to induce lethal mutagenesis against MNV 
[33, 40, 41]. It has also been approved as an influenza treatment in Japan [42]. 
Although it was evidenced to inhibit replication of several viruses such as Ebola 
virus, hantaviruses, flaviviruses, and arena viruses with in vitro and mouse models, 
it showed poor antiviral activity for MNV replication in cell cultures [33, 43].
3.1.1.3 Ribavirin (RBV)
The RBV (1-α-D-ribofuranosyl-1,2,4-triazole-3- carboxamide) is a guanosine 
analog and the first drug found to inhibit MNV and human NoV replication in 2007. 
It was originally used as clinical treatments for HCV, Lassa fever, respiratory syncy-
tial virus, and hepatitis E viruses (Snell, 2001). The EC50 was 40 μM for Norwalk 
replicon and had 82% reduction of replicon genome at 100 μM [33, 44]. However, 
since some studies found RBV had poor inhibition of MNV and Norwalk replicon, 
coupled with numerous adverse effects, it is not a desirable NoV antivirals [45].
3.1.1.4 CMX521
CMX521 is a novel antiviral drug discovered by the Chimerix. The press release 
reported that it is at phase I clinical trial and has potent antiviral activity against 
NoV. Pharmacokinetics, safety, tolerability were evaluated in approximately 50 
healthy adults [33, 46].
3.1.1.5 Non-nucleoside inhibitors
3.1.1.5.1 Suramin and related derivative
Suramin is a sleeping sickness medication that was found to effectively inhibit 
in vitro activities of MNV and human polymerases [47]. NF03, which is the smaller 
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derivative of suramin, could inhibit mouse and human NoV RdRp activities with 
IC50s of 200 and 71.5 nM, respectively [47]. NF023 was also a smaller suramin 
derivative that could inhibit both human and mouse NoV RdRp activities. In addi-
tion, naphthalene disulfonate (NAF2) and tetrasodium (PPNDS) were also found 
to be capable of inhibiting human NoV RdRp [33, 48, 49]. However, despite of the 
promising effectiveness, the antiviral efficacy of these compounds are reduced due 
to the poor bioavailability and cell permeability [33, 48, 50, 51] Another study also 
identified some compounds (NIC02 [2.2.11], NIC04, NIC10, and NIC12) by using 
viral enzyme activity assays. MNV replication and Norwalk replicon were both 
found to be inhibited [33, 52].
3.1.2 Protease inhibitors
Rupintrivir is one of the protease inhibitors (PIs) discovered for NoV. In addi-
tion to the potential efficacy of this compound, it also possesses broad-spectrum 
antiviral effects against coronaviruses, picornaviruses, and caliciviruses such 
as FCV, MNV, and Norwalk replicon [33, 53]. However, it was also found that 
Rupintrivir had limited bioavailability and pharmacokinetics due to the low 
potency in vivo. As a result, the Rupintrivir may not be an ideal therapy for the 
NoV infection [33, 47].
3.1.3 Protein targets
Deubiquitinase (DUB) inhibitor is one of the recently discovered NoV antivirals 
that can regulate ubiquitin-ubiquitin-proteasome system [33, 54, 55–57]. WP1130 
[2.4.1] is a small synthetic DUB inhibitor found to inhibit NoV and MNV replication 
through unfolded protein response. However, due to the low bioavailability, show 
that MNV inhibition was limited to small intestine in mice [33, 56].
3.1.4 Immunomodulators
Immunomodulators are found to be a potent therapeutic antiviral for NoV 
since they could induce powerful host response. Interferons are one of the best 
immunomodulators and many studies have shown that type I, type II IFNs, and 
their receptors could provide protection against human and murine NoV infections 
[33, 58–66]. The type III IFNs (IFN-λ) has been recently explored and was shown to 
be capable of preventing persistent MNV infection in mice system [33, 67, 68].
3.1.5 Compounds with unknown targets
Currently, the only NoV antiviral candidate that completed clinical trials is 
called NTZ. The NTZ was found to have a good antimicrobial activity against 
various bacterial, viral, and protozoan infections. It is also an FDA-approved drug 
for the treatment of Giardia and Crytosporidium infections [33, 69]. Treatment of 
NTV was found to reduce durations of gastroenteritis symptoms when compared 
to the placebo (P = 0.0295) in the phase II randomized double-blind trial [33, 70]. 
Another study also evidenced that NTZ was capable of curing immunosuppressed 
transplant patient with NoV infection and 10 consecutive days of gastroenteritis 
symptoms [33, 71]. It was also recently found that NTZ could potently inhibit GI 
NoV replicon at a clinically relevant concentration (5 ug mL−1) [33, 72].
NoV in stool samples from a pediatric patient with chronic NoV following 
kidney transplantation was also shown to be cleared [73]. There have been some 
discrepancy regarding the effectiveness of NTZ for NoV treatment [33, 74–77]. 
Norovirus
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However, since NTZ is currently the only therapeutic method except from RBV and 
immunoglobulins, it is still supportive to NoV infected-patients.
3.2 Remarks on gastroenteritis symptoms in coronavirus
Acute gastroenteritis symptoms including diarrhea, vomiting and abdominal 
pain are not only limited to NoV infections. Viruses such as rotavirus, astro-
virus, calicivirus are common etiologic agents for acute gastroenteritis [78]. 
Coronaviruses, which is the genus of the most concerned issue of severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in the world, is also 
identified as causative agent of diarrhea [78]. It was reported that approximately 
12% of COVID-19 patients experienced gastrointestinal symptoms based on a 
systematic review and meta-analysis of published studies from November 1, 2019 
to March 30, 2020 [79]. One study observed mild initial gastrointestinal symp-
toms (e.g., diarrhea, abdominal pain, nausea, and vomiting) preceded the fever 
and respiratory problems. The study also found the fecal test remained positive 
post 12 day of disease onset. Longer durations between symptom onset and fecal 
virus-positive and viral clearance were also observed [80, 81]. Another study also 
found gastrointestinal symptoms such as diarrhea (24.2%), anorexia (17.9%), and 
nausea (17.9%) occurred in COVID-19 patients [80, 82]. Results from a systematic 
meta-analysis study also showed the incidence rate of diarrhea from 2–50% of the 
COVID-19 positive cases [80, 83]. Furthermore, according to clinical cases, intesti-
nal damages were found to be manifested after respiratory symptoms [80, 84].
Taken together, since gastroenteritis symptoms could commonly occur in 
various virus-infected individuals. It is not easy to differentiate if it is caused by the 
SARS-CoV-2 by simply observing the symptoms of patients. It was also indicated 
that patients with gastroenteritis symptoms also take a longer time to present to 
healthcare systems and to be confirmed after diagnosis [85]. Further detection of 
SARS-CoV-2 RNA or diagnosis of other symptoms correlated with SARS-CoV-2 
disease onset are required. Precautions should also be taken carefully for the 
infectiveness and transmissibility of SARS-CoV-2 in COVID-19 positive feces in 
stool [80].
4. Conclusions
NoV has been a major cause leading to acute gastroenteritis and hundreds of 
thousands mortalities annually. Also, significant economic and social impacts have 
been resulted from this pathogen despite preclinical or clinical research are inten-
sively ongoing. Technical issues such as the limitations in the current used human 
culture systems need to be overcome for the development of effective vaccines 
or drugs. Epidemiological studies also suggest that development of multivalent 
vaccines for both GI and GII NoV are the only solution for broad-spectrum and 
effective protection. As mentioned previously in this chapter, it is promising that 
several vaccines have gone through clinical trials and many drugs are currently in 
clinical use. However, it is of note that since clinical trials mainly enrolled adults, 
it would be necessary to evaluate the safety and effectiveness of the candidate 
vaccines in all age groups since NoV poses greater threats to children and elderly 
groups. To facilitate the progress of vaccine/drug developments for NoV antivirals, 
exploration of the relationship between viral strains and host human immunogenic-
ity and antigen types at clinical practices would also be helpful. Improvements in 
diagnostic methods and outbreak containment or management may help to alleviate 
the epidemics.
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